Non-alcoholic Steatohepatitis Treatment Companies and Competitive Landscape
The global non-alcoholic steatohepatitis treatment market size is calculated at USD 7.75 billion in 2024, grew to USD 9.93 billion in 2025, and is projected to reach around USD 92.5 billion by 2034. The market is expanding at a CAGR of 28.14% between 2025 and 2034.
Top Companies in the Non-alcoholic Steatohepatitis Treatment Market
- AstraZeneca
- Eli Lilly & Company
- Galectin Therapeutics
- Galmed Pharmaceuticals, Ltd.
- Intercept Pharmaceuticals
- Madrigal Pharmaceuticals
- Mayo Foundation for Medical Education & Research
- NGM Biopharmaceuticals
- Novo Nordisk A/S
- Pfizer, Inc.
- Shilpa Medicare
- Viking Therapeutics, Inc.
Recent Developments in the Non-alcoholic Steatohepatitis Treatment Market
- In June 2024, Eli Lilly and Company announced positive results from the SYNERGY-NASH phase 2 clinical trial assessing the investigational role of tirzepatide in NASH patients with or without type 2 diabetes. The trial results showed that patients reported an absence of MASH with no worsening of fibrosis on liver histology.
- In June 2024, Viking Therapeutics, Inc. announced positive results of 52-week histologic data from its Phase 2b VOYAGE study involving VK2809 for treating NASH. The patients achieved a significant reduction in liver fat content after receiving VK2809.
